Novartis AG (Spons. ADRS) Stock , NVS

118.14 -1.36 -1.13%

03:59:59 PM EDT 6/16/2025 BTT

News

On Friday 06/13/2025 the closing price of the Novartis AG (Spons. ADRS) share was $119.50 on BTT. Compared to the opening price on Friday 06/13/2025 on BTT of $119.34, this is a gain of 0.13%.

Novartis Stock Snapshot

102.35

100.00

135.76

100.00

6/16/2025

3:59 PM

66,651.00

119.50

119.05

1.90 B

118.06

119.50

118.14

96.09

120.92

118.14

3.28

3.37

16.45

100.00

5.92

22.30

8.66

Novartis News More News

TipRanks 14h

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN)

Zacks 4d

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

TipRanks 5d

Senators to propose ban on drug ads to consumers, WSJ reports

TipRanks 5d

Novartis announces results from APPULSE-PNH study of Fabhalta

TipRanks 5d

RFK Jr. names eight members to vaccine panel, WSJ reports

Historical Prices for Novartis

Loading..
Date	Open	Close	Daily High	Daily Low

Price change over selected period: 0% 0

Novartis Analyst Data

Total Analysts: 4

Buy Ratings: 3 Neutral Ratings: 1 Sell Ratings: 0

Price *Price Target

Lowest: 114.00 Median: 116.63 Highest: 122.50

*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Novartis Analyst Opinions

Date	Analyst	Rating	Price
02/13/25	UBS	Downgraded to Hold		neutral
07/02/24	Jefferies & Company Inc.	Maintained Buy	$122.5	gut
04/24/24	BMO Capital Markets	Maintained Buy	$116	gut
02/23/24	BMO Capital Markets	Maintained Buy	$114	gut
01/23/24	Morgan Stanley	Maintained Hold	$114	neutral
09/25/23	Morgan Stanley	Upgraded to Hold		neutral

Novartis Estimates* in USD

	2025	2026	2027	2028	2029
Revenue	54,170	55,302	56,580	58,609	59,979
Dividend	4.04	4.20	4.37	-	4.92
Dividend Yield (in %)	3.38 %	3.52 %	3.65 %	3.78 %	4.12 %
EPS	8.59	8.92	9.48	10.26	10.83
P/E Ratio	13.90	13.40	12.61	11.65	11.04
EBIT	21,284	21,136	22,098	23,294	24,427
EBITDA	21,972	22,348	23,194	24,587	28,548
Net Profit	17,063	17,483	18,228	19,292	19,592
Net Profit Adjusted	17,063	17,483	18,228	19,292	19,592
Pre-Tax Profit	20,085	-	21,585	21,907	23,227
Pre-Tax Profit Reported	16,320	17,004	17,883	20,343	23,984
EPS (Non-GAAP) ex. SOE	-	-	-	-	-
EPS (GAAP)	6.88	7.30	7.78	-	9.71
Gross Income	44,236	45,665	46,406	50,029	50,962
Cash Flow from Investing	-2,874	-2,157	-2,450	-2,026	-1,966
Cash Flow from Operations	18,881	19,694	19,954	22,589	23,712
Cash Flow from Financing	-16,032	-11,327	-13,136	-14,128	-14,267
Cash Flow per Share	9.08	9.58	10.05	-	14.20
Free Cash Flow	15,288	15,872	16,053	17,951	19,424
Free Cash Flow per Share	7.14	7.84	8.38	11.63	12.73
Book Value per Share	23.89	26.53	29.51	-	30.90
Net Debt	16,219	11,081	5,515	2,228	-170
Research & Development Exp.	10,096	10,325	10,526	10,808	10,990
Capital Expenditure	2,515	2,700	2,868	2,485	2,070
Selling, General & Admin. Exp.	13,152	13,015	12,977	13,224	13,288
Shareholder’s Equity	45,365	49,150	53,433	53,403	62,116
Total Assets	91,660	108,779	112,904	110,858	118,298

	Previous Quarter ending 03/31/25	Current Quarter ending 06/30/25	Next Quarter ending 09/30/25	Current Year ending 12/31/25	Next Year ending 12/31/26
Earnings Estimates
No. of Analysts	-	7	7	19	19
Average Estimate	-	2.307 USD	2.117 USD	8.594 USD	8.919 USD
Year Ago	-	1.597 USD	1.585 USD	5.916 USD	-
Publish Date	-	7/17/2025	10/28/2025	-	-
Revenue Estimates
No. of Analysts	-	6	6	18	17
Average Estimate	-	13,996 USD	13,390 USD	54,170 USD	55,302 USD
Year Ago	-	12,512 USD	12,823 USD	50,317 USD	-
Publish Date	-	7/17/2025	10/28/2025	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

	2024	2023	2022	2021	2020	2019	2018
Sales	50,317.00	45,440.00	50,545.00	51,626.00	48,659.00	47,498.00	51,900.00
Change of sales in %	10.73	-10.10	-2.09	6.10	2.44	-8.48	5.68
Gross profit on sales	37,293.00	32,867.00	35,239.00	35,759.00	33,538.00	33,073.00	33,493.00
Gross profit on sales change in %	13.47	-6.73	-1.45	6.62	1.41	-1.25	4.88
Operating income	15,427.00	11,867.00	12,264.00	11,602.00	10,819.00	10,092.00	9,748.00
Operating income change in %	30.00	-3.24	5.71	7.24	7.20	3.53	6.13
Income before tax	13,678.00	9,136.00	8,380.00	10,798.00	9,205.00	8,281.00	7,397.00
Income before tax change in %	49.72	9.02	-22.39	17.31	11.16	11.95	-6.26
Income after tax	11,941.00	8,568.00	6,955.00	24,021.00	8,072.00	7,142.00	12,611.00
Income after tax change in %	39.37	23.19	-71.05	197.58	13.02	-43.37	63.72

Balance Sheet in Mio. USD

	2024	2023	2022	2021	2020	2019	2018
Total liabilities	62,637.00	57,074.00	62,342.00	68,062.00	75,523.00	62,862.00	66,954.00
Long-term liabilities per share	-	-	-	15.11	18.82	15.27	16.16
Equity	44,126.00	46,750.00	59,423.00	67,822.00	56,666.00	55,551.00	78,692.00
Equity change in %	-5.62	-21.36	-12.29	19.54	2.03	-29.43	5.99
Balance sheet total	106,763.00	103,824.00	121,765.00	135,884.00	132,189.00	118,413.00	145,646.00
Balance sheet total change in %	2.83	-14.73	-10.39	2.80	11.63	-18.70	9.32

Key Data in USD

	2024	2023	2022	2021	2020	2019	2018
Sales per share	24.73	21.72	23.01	22.84	21.19	20.48	22.14
P/E ratio (year end quote, basic EPS)	16.45	14.12	28.45	8.17	26.64	30.81	15.78
P/E ratio (year end quote, diluted EPS)	16.58	14.22	28.66	8.23	26.86	31.19	15.95
Dividend yield in %	3.37	3.17	2.51	2.47	2.20	2.12	2.15
Equity ratio in %	41.33	45.03	48.80	49.91	42.87	46.91	54.03
Debt ratio in %	58.67	54.97	51.20	50.09	57.13	53.09	45.97

Novartis Dividend Calendar

Date	Name	Dividend	*yield	Currency
2024	Novartis AG (Spons. ADRS)	3.28	3.37	USD
2023	Novartis AG (Spons. ADRS)	3.20	3.17	USD
2022	Novartis AG (Spons. ADRS)	2.27	2.51	USD
2021	Novartis AG (Spons. ADRS)	2.16	2.47	USD
2020	Novartis AG (Spons. ADRS)	2.08	2.20	USD
2019	Novartis AG (Spons. ADRS)	2.01	2.12	USD
2018	Novartis AG (Spons. ADRS)	1.84	2.15	USD
2017	Novartis AG (Spons. ADRS)	2.49	2.96	USD
2016	Novartis AG (Spons. ADRS)	2.30	3.16	USD
2015	Novartis AG (Spons. ADRS)	2.30	2.68	USD
2014	Novartis AG (Spons. ADRS)	2.26	2.44	USD
2013	Novartis AG (Spons. ADRS)	2.34	2.91	USD
2012	Novartis AG (Spons. ADRS)	2.06	3.25	USD
2011	Novartis AG (Spons. ADRS)	2.11	3.68	USD
2010	Novartis AG (Spons. ADRS)	2.01	3.40	USD
2009	Novartis AG (Spons. ADRS)	1.65	3.04	USD

*Yield of the Respective Date

Novartis Calendar

Event	Estimate	Info	Date
Earnings Report	2.307 USD	Q2 2025 Earnings Release	07/17/2025
Earnings Report	2.117 USD	Q3 2025 Earnings Release	10/28/2025
Earnings Report	1.954 USD	Q4 2025 Earnings Release	02/04/2026
Earnings Report	2.040 USD	Q1 2026 Earnings Release	04/28/2026
Earnings Report	2.120 USD	Q2 2026 Earnings Release	07/21/2026
Earnings Report	2.150 USD	Q3 2026 Earnings Release	11/03/2026

Novartis Past Events

Event	Actual EPS	Info	Date
Earnings Report	1.830 USD	Q1 2025 Earnings Release	04/29/2025
Annual General Meeting	5.920 USD	Annual General Meeting	03/07/2025
Earnings Report	1.420 USD	Q4 2024 Earnings Release	01/31/2025
Earnings Report	1.580 USD	Q3 2024 Earnings Release	10/29/2024
Earnings Report	1.600 USD	Q2 2024 Earnings Release	07/18/2024
Earnings Report	1.310 USD	Q1 2024 Earnings Release	04/23/2024
Annual General Meeting	7.150 USD	Annual General Meeting	03/05/2024
Earnings Report	4.140 USD	Q4 2023 Earnings Release	01/31/2024
Earnings Report	0.850 USD	Q3 2023 Earnings Release	10/24/2023
Earnings Report	1.110 USD	Q2 2023 Earnings Release	07/18/2023
Earnings Report	1.090 USD	Q1 2023 Earnings Release	04/25/2023
Annual General Meeting	3.190 USD	Annual General Meeting	03/07/2023
Earnings Report	0.690 USD	Q4 2022 Earnings Release	02/01/2023
Earnings Report	0.730 USD	Q3 2022 Earnings Release	10/25/2022
Earnings Report	0.770 USD	Q2 2022 Earnings Release	07/19/2022
Earnings Report	1.000 USD	Q1 2022 Earnings Release	04/26/2022
Annual General Meeting	10.710 USD	Annual General Meeting	03/04/2022
Earnings Report	7.290 USD	Q4 2021 Earnings Release	02/02/2022

Novartis Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.